Empagliflozin 25mg
$165.00 – $420.00

| Product name | Voglibose-Metformin 0.2mg-500mg |
|---|---|
| Active Ingredient | Voglibose-Metformin |
| Dosage | 0.2mg-500mg |
| Drug Type | Tablets |
| Indication | Type 2 Diabetes |
| Manufacturer | USV Ltd |
Total $56.10
Voglibose–Metformin 0.2mg–500mg tablet is a prescription medicine used to control type 2 diabetes mellitus. Doctors such as a diabetologist or physician prescribe it when blood sugar levels are not well controlled with diet, exercise, or a single medicine.
This tablet combines voglibose 0.2mg and metformin 500mg. Both medicines work in different ways to reduce blood sugar. The combination helps control post-meal sugar spikes and fasting glucose levels more effectively.
Type 2 diabetes is a long-term condition where the body cannot use insulin properly. This leads to high blood sugar levels. Over time, uncontrolled diabetes can damage the heart, kidneys, eyes, and nerves.
Voglibose–Metformin 0.2mg–500mg controls blood sugar through two complementary actions.
Voglibose works in the intestine. It slows down the digestion of carbohydrates from food. This helps reduce the sudden rise in blood sugar after meals.
Metformin works mainly in the liver and body tissues. It reduces glucose production in the liver and improves how the body uses insulin.
Together, these actions help maintain more stable blood sugar levels throughout the day. This reduces sharp spikes after meals and supports better overall glucose control.
Doctors prescribe Voglibose–Metformin tablet for type 2 diabetes management. A diabetologist or physician decides the treatment plan based on blood sugar levels and patient response.
This medicine helps control post-meal blood sugar spikes, which are common in diabetes.
It supports better fasting blood sugar control when combined with diet and exercise.
Patients with high HbA1c levels may benefit from this combination therapy.
Doctors may recommend it when a single medicine does not provide enough control.
Voglibose mechanism of action blocks enzymes in the intestine that break down complex carbohydrates. This slows glucose absorption and reduces post-meal sugar rise.
Metformin mechanism of action lowers glucose production in the liver and improves insulin sensitivity. This helps body cells use glucose more effectively.
By combining these two mechanisms, the medicine provides better control over daily blood sugar fluctuations.
Most people tolerate Voglibose–Metformin well, but some mild side effects can occur.
Some patients may experience gas, bloating, or abdominal discomfort due to slowed digestion.
A few individuals may notice loose stools or mild diarrhea, especially at the beginning.
Some people may feel nausea or stomach upset.
Occasionally, headache or dizziness may occur.
Rarely, low blood sugar (hypoglycemia) can happen, especially when used with other diabetes medicines.
Very rarely, metformin may cause lactic acidosis, especially in patients with kidney problems.
Use Voglibose–Metformin 0.2mg–500mg tablet only under the supervision of a diabetologist or physician.
Take the tablet with meals to reduce stomach-related side effects and improve effectiveness.
Follow a balanced diet and regular exercise plan for better diabetes control.
Inform your doctor if you have kidney disease, liver problems, or digestive issues before starting treatment.
Regular monitoring of blood sugar levels and HbA1c is important during therapy.
Avoid excessive alcohol intake, as it may increase side effects.
Do not skip meals while taking this medicine, as it may affect blood sugar balance.
Take the medicine regularly at the same time each day for consistent results.
If prescribed, you can order Voglibose–Metformin 0.2mg–500mg tablets online from trusted pharmacy sources and continue your diabetes treatment safely under medical supervision.
This content is for educational purposes only. It does not replace medical advice. Always consult a qualified healthcare professional such as a diabetologist or physician before starting or stopping Voglibose–Metformin 0.2mg–500mg tablet.